Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.083
Neutral
RSI(14)
35.102
Neutral
STOCH(KDJ)(9,3,3)
31.544
Neutral
ATR(14)
0.097
Low Volatility
CCI(14)
-37.791
Neutral
Williams %R
67.993
Sell
TRIX(12,20)
-1.423
Sell
StochRSI(14)
100.000
Buy
Search
Purple Biotech Ltd
PPBTAdd to Watchlist
1.400USD
-0.010-0.71%
Close 07-31 16:00（ET）Quotes delayed by 15 min
13.01MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.71%
5 Days
-2.10%
1 Month
-16.67%
6 Months
-76.82%
Year to Date
-78.71%
1 Year
-93.52%
Key Figures
1.450Open
1.450High
17.18KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.18%Turnover Ratio
1.370Prev. Close
1.340Low
12.57KTurnover
LossP/E Static
1.34P/B
0.00%Div Yield TTM
-97.02%ROA
29.00052wk High
2.37Volume Ratio
-7.24MNet Profit
9.29MShares
-5.4960EPS TTM
0.61Beta
-123.95%ROE
2.52052wk Low
8.03%Amplitude
--Gross Margin
13.01MMarket Cap
-3.71Reward/Risk
5.23%Risk Rate
TradingKey Stock Score of Purple Biotech Ltd
Currency: USD Updated: 2026-07-31Key Insights
Purple Biotech Ltd's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 142 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Purple Biotech Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Purple Biotech Ltd Highlights
StrengthsRisks
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.25, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 121.71K shares, increasing 41.59% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.98.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
30.000
Target Price
+2073.91%
Upside Space
Purple Biotech Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
30.000
Target Price
+2073.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Purple Biotech Ltd
PPBT
1
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.392
Buy
MA10
1.395
Buy
MA20
1.467
Sell
MA50
1.978
Sell
MA100
3.055
Sell
MA200
4.909
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Purple Biotech Ltd Info
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Ticker SymbolPPBT
CompanyPurple Biotech Ltd
CEOEfron (Gil)
Websitehttps://purple-biotech.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Purple Biotech Ltd (PPBT)?
The current price of Purple Biotech Ltd (PPBT) is 1.40.
What is the symbol of Purple Biotech Ltd?
The ticker symbol of Purple Biotech Ltd is PPBT.
What is the 52-week high of Purple Biotech Ltd?
The 52-week high of Purple Biotech Ltd is 29.00.
What is the 52-week low of Purple Biotech Ltd?
The 52-week low of Purple Biotech Ltd is 2.52.
What is the market capitalization of Purple Biotech Ltd?
The market capitalization of Purple Biotech Ltd is 13.01M.
Is Purple Biotech Ltd (PPBT) currently rated as Buy, Hold, or Sell?
According to analysts, Purple Biotech Ltd (PPBT) has an overall rating of Buy, with a price target of 30.00.
What is the Earnings Per Share (EPS TTM) of Purple Biotech Ltd (PPBT)?
The Earnings Per Share (EPS TTM) of Purple Biotech Ltd (PPBT) is -5.50.